Sponsors (24)
The bill directs modest federal funds and coordinated education, data collection, and research toward improving diagnosis, treatment, and equity for people with endometriosis, while imposing modest fiscal and administrative costs and privacy/implementation risks and not guaranteeing immediate new services.
Women and people with endometriosis will see increased national recognition, public education, clinician outreach, and a centralized clearinghouse of evidence that should improve diagnosis, clinician awareness, and patient access to information.
People with endometriosis will benefit from a sustained federal research investment ($50M/year FY2026–2030) to expand research, improve treatments, and pursue potential cures.
Low-income and Medicaid/CHIP enrollees may gain from HHS analyses of claims and T‑MSIS data to identify barriers to care and inform policy changes that improve access.
Taxpayers face modest new federal spending (notably $50M/year for NIH plus education/dissemination and study funds), increasing budgetary costs.
Insurers, employers, and state Medicaid programs may incur additional administrative and implementation costs from reporting, data submissions, and system changes required to collect and stratify endometriosis data.
Collecting and sharing sensitive health data increases privacy and civil‑liberties risks for patients with endometriosis despite required privacy protections.
Based on analysis of 3 sections of legislative text.
Authorizes federal research, data collection, public education, clinician outreach, and a disparities study on endometriosis, with multi-year funding authorizations for FY2026–FY2030.
Introduced December 11, 2025 by Nikema Williams · Last progress December 11, 2025
Directs federal health agencies to expand research, data collection, public education, and clinician outreach about endometriosis and to study disparities in diagnosis and treatment. Provides multi-year authorized funding for NIH research, HHS public education and clinician information programs, and funds a National Academies study; requires HHS analysis of barriers to treatment using claims data and a report to Congress within two years.